Cubist Pharmaceuticals Announces Positive Results From Drug Trials

Cubist Pharmaceuticals, Inc. CBST announced this morning that it had positive results from two Phase 2 trials, CXA-201 and CDAD Program. The company announced that CXA-201 is being used for intra-abdominal infections . “Positive results from these two Phase 2 clinical trials are significant milestones for our pipeline, as well as our ongoing efforts to become a global acute care leader,” said Steven Gilman, Ph.D., Executive Vice President of Research and Development. “There is a large and growing need for new and better antibiotics across the globe, and we are very pleased with these positive results.” Shares closed at $33.69 yesterday.